What is the clinical evidence from this study?

Study design: Review. Population: Dyslipidaemia.

What does this research mean for the field?

Dyslipidaemia remains a primary driver of cardiovascular disease, and its clinical management is being transformed by advanced lipid biomarkers, innovative imaging modalities, and emerging targeted therapeutics such as RNA-based treatments. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the pathophysiology, epidemiological trends, diagnostic advances, and emerging therapeutic approaches for dyslipidaemia in mitigating cardiovascular risk.

September 10, 2026Russian Journal of Bioorganic Chemistry

Precision medicine and multi-omics frameworks offer transformative therapeutic potential for managing dyslipidaemia.

View Full Paper

Ask AI

Bookmark

Key result

This review evaluates the pathophysiology, epidemiology, and emerging therapeutic strategies for dyslipidaemia, highlighting the transformative potential of precision medicine and multi-omics frameworks.

Authors

AQAmjad Mahmood Qadir RORebaz Anwar Omer HBHemn A.H. Barzani

Discussion

Member takes

Overview

Review uncovers evolving diagnostic biomarkers and RNA-targeted therapeutics for dyslipidaemia across diverse populations, highlighting precision medicine approaches to reduce cardiovascular risk.

Key Points

To review the pathophysiology, epidemiological trends, diagnostic advances, and emerging therapeutic approaches for dyslipidaemia in mitigating cardiovascular risk.
Synthesized molecular, genetic, and epidemiological evidence differentiating primary hereditary dyslipidaemias from secondary acquired etiologies.
Evaluated diagnostic innovations, including advanced lipid biomarkers and imaging modalities, alongside pharmacological regimens ranging from statins to RNA-targeted therapies.
Advanced lipid biomarkers and high-resolution imaging modalities substantially improve cardiovascular risk stratification beyond conventional lipid panels.
Therapeutic strategies have expanded from lifestyle modification and standard statin or ezetimibe regimens to PCSK9 inhibitors and emerging RNA-targeted therapeutics, though patient adherence remains a major clinical challenge.

PICO

Population

Dyslipidaemia

Cite This Study

Qadir et al. (2026) conducted a review in Dyslipidaemia. This review evaluates the pathophysiology, epidemiology, and emerging therapeutic strategies for dyslipidaemia, highlighting the transformative potential of precision medicine and multi-omics frameworks.

synapsesocial.com/papers/6aa27bcf58559d80afc75445 https://doi.org/10.1134/s1068162025603581

View Full Paper

Ask AI

Bookmark

September 10, 2026Russian Journal of Bioorganic Chemistry

Precision medicine and multi-omics frameworks offer transformative therapeutic potential for managing dyslipidaemia.

View Full Paper

Ask AI

Bookmark

Key result

Authors

AQAmjad Mahmood Qadir RORebaz Anwar Omer HBHemn A.H. Barzani

Discussion

Member takes

Overview

Review uncovers evolving diagnostic biomarkers and RNA-targeted therapeutics for dyslipidaemia across diverse populations, highlighting precision medicine approaches to reduce cardiovascular risk.

Key Points

To review the pathophysiology, epidemiological trends, diagnostic advances, and emerging therapeutic approaches for dyslipidaemia in mitigating cardiovascular risk.
Synthesized molecular, genetic, and epidemiological evidence differentiating primary hereditary dyslipidaemias from secondary acquired etiologies.
Evaluated diagnostic innovations, including advanced lipid biomarkers and imaging modalities, alongside pharmacological regimens ranging from statins to RNA-targeted therapies.
Advanced lipid biomarkers and high-resolution imaging modalities substantially improve cardiovascular risk stratification beyond conventional lipid panels.
Therapeutic strategies have expanded from lifestyle modification and standard statin or ezetimibe regimens to PCSK9 inhibitors and emerging RNA-targeted therapeutics, though patient adherence remains a major clinical challenge.

PICO

Population

Dyslipidaemia

Cite This Study

synapsesocial.com/papers/6aa27bcf58559d80afc75445 https://doi.org/10.1134/s1068162025603581

View Full Paper

Ask AI

Bookmark